
Aduhelm for Alzheimer’s Discontinued. Is Leqembi Any Better?
Biogen reprioritize resources allocated to ADUHELM® to advance LEQEMBI®.
Biogen reprioritize resources allocated to ADUHELM® to advance LEQEMBI®.
At long last, we finally have a disease-modifying drug for Alzheimer’s. The FDA recently approved a new drug that promises to slow the progression of the disease. Only five Alzheimer’s treatments have been approved by the FDA up until a decade ago, and this is only the second to address the progression of the disease.
FDA-approved ADLARITY is the once-weekly donepezil patch. See how it compares to donepezil / Aricept / Ebixa tablets for Alzheimer’s.
A neuroradiologist at the Mayo Clinic in Jacksonville, FL warns that increased use of monoclonal antibody treatment for Alzheimer’s has also led to the discovery of amyloid-related imaging abnormalities — ARIA. Find out more.
The first drugs for Alzheimer’s disease emerged in the 1990s, but since then there has been a wave of clinical trial failures, major companies pulling resources from neuroscience R&D, and progress.
Dr. Robert Przybelski has prescribed lecanemab to real-life patients, and discusses his experience prescribing and administering the treatment.
Now, a third new Alzheimer’s drug expected to be approved by the Food and Drug Administration (FDA),. The field of new drugs is beginning to show progress in the fight to slow the disease.
The FDA has approved generic lecanemab (brand name Leqembi®). The new drug can slow the progression of Alzheimer’s. Two top doctors discuss the pros and cons.
First drug to modestly slow Alzheimer’s cognitive decline, based on 1,800 patients.
The FDA Advisory Committee’s endorsement of Leqembi paves way for traditional approval, ushers in a new era for Alzheimer’s
Here’s Teddy Mac and his son Simon singing Oklahoma – one of his showstoppers – from a few years ago.
This isn’t any ordinary garden! It’s home to a very special group of people living well with Alzheimer’s.
The Housing Learning and Improvement Network looks at the design process and philosophy behind creating a successful Extra Care scheme.
What are the early symptoms of Alzheimer’s? When to get a professional evaluation.
SHORT-TERM MEMORY lapses are obvious signs of Alzheimer’s, but other tell-tale signals begin to show much earlier. Learn how to look for semantic impairments, such as simple questions about size.
Three important dementia studies focus on HS-AGING, a type of dementia almost as common as Alzheimer’s in the 85+ group. Yet few people have heard of it. Why? What makes it different?
An intriguing study of 120 grandmothers might surprise you. Doctors know socially engaged people have better cognition and less dementia. But can a person get too much of a good thing? What’s the right balance?
No spam, only news and updates.